Double placebo design in a prevention trial for Alzheimer's disease

Research output: Contribution to journalArticle

Abstract

The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalControlled Clinical Trials
Volume23
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Alzheimer Disease
Placebos
Anti-Inflammatory Agents
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Placebo control
  • Primary prevention
  • Randomized clinical trial

ASJC Scopus subject areas

  • Pharmacology

Cite this

Double placebo design in a prevention trial for Alzheimer's disease. / Martin, Barbara K.; Meinert, Curtis L; Breitner, John C.S.

In: Controlled Clinical Trials, Vol. 23, No. 1, 2002, p. 93-99.

Research output: Contribution to journalArticle

@article{8409af40e458415eb164ea3772ce616a,
title = "Double placebo design in a prevention trial for Alzheimer's disease",
abstract = "The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.",
keywords = "Alzheimer's disease, Placebo control, Primary prevention, Randomized clinical trial",
author = "Martin, {Barbara K.} and Meinert, {Curtis L} and Breitner, {John C.S.}",
year = "2002",
doi = "10.1016/S0197-2456(01)00189-1",
language = "English (US)",
volume = "23",
pages = "93--99",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Double placebo design in a prevention trial for Alzheimer's disease

AU - Martin, Barbara K.

AU - Meinert, Curtis L

AU - Breitner, John C.S.

PY - 2002

Y1 - 2002

N2 - The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.

AB - The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.

KW - Alzheimer's disease

KW - Placebo control

KW - Primary prevention

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0036174553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036174553&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(01)00189-1

DO - 10.1016/S0197-2456(01)00189-1

M3 - Article

C2 - 11852171

AN - SCOPUS:0036174553

VL - 23

SP - 93

EP - 99

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 1

ER -